US 12,305,185 B2
Expression vector and method
Christopher Layton, Queensland (AU); and Jason Steel, Queensland (AU)
Assigned to MOUNT SPEC INVESTMENTS PTY LTD, Queensland (AU)
Appl. No. 16/963,880
Filed by MOUNT SPEC INVESTMENTS PTY LTD, Queensland (AU)
PCT Filed Jan. 23, 2019, PCT No. PCT/AU2019/050046
§ 371(c)(1), (2) Date Jul. 22, 2020,
PCT Pub. No. WO2019/144186, PCT Pub. Date Aug. 1, 2019.
Claims priority of application No. 2018900206 (AU), filed on Jan. 23, 2018.
Prior Publication US 2021/0207166 A1, Jul. 8, 2021
Int. Cl. C12N 15/86 (2006.01); A61K 9/00 (2006.01); A61K 31/192 (2006.01); A61K 31/65 (2006.01); A61P 27/02 (2006.01); A61P 37/06 (2006.01); C12N 7/00 (2006.01); A61K 48/00 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 9/0048 (2013.01); A61K 31/192 (2013.01); A61K 31/65 (2013.01); A61P 27/02 (2018.01); A61P 37/06 (2018.01); C12N 7/00 (2013.01); A61K 48/00 (2013.01); C12N 2750/14143 (2013.01); C12N 2800/30 (2013.01); C12N 2830/003 (2013.01); C12N 2830/006 (2013.01); C12N 2830/20 (2013.01)] 10 Claims
 
1. An expression vector comprising
a) a kill switch comprising a first site-specific recombination sequence and a second site-specific recombination sequence;
b) a regulatable element operably linked to a nucleic acid sequence encoding a therapeutic molecule, wherein activity of the regulatable element is regulated by a regulator compound; and
c) a constitutive promoter operably linked to a nucleic acid sequence encoding a regulator compound-binding polypeptide which is capable of binding a regulator compound, wherein upon binding the regulator compound, the regulator compound-binding polypeptide regulates expression of the therapeutic molecule,
wherein activation of the kill switch by recombination between the first site-specific recombination sequence and the second site-specific recombination sequence silences expression of the nucleic acid encoding the therapeutic molecule from the vector.